MGMT Gene Promoter Methylation as a Potent Prognostic Factor in Glioblastoma Treated With Temozolomide-Based Chemoradiotherapy: A Single-Institution Study

Article ID	Journal	Published Year	Pages	File Type
8224320	International Journal of Radiation OncologyBiologyPhysics	2012	7 Pages	PDF

Abstract

We confirmed that MGMT gene methylation is a potent prognostic factor in patients with GBM. Our results suggest that early postoperative radiotherapy and a high total/subtotal resection rate might further improve the outcome.

Keywords

O6-methylguanine-DNA methyltransferase Radiotherapy Prognostic factor Methylation Glioblastoma

Related Topics

Physical Sciences and Engineering Physics and Astronomy Radiation

Preview

MGMT Gene Promoter Methylation as a Potent Prognostic Factor in Glioblastoma Treated With Temozolomide-Based Chemoradiotherapy: A Single-Institution Study

Authors

Young Suk M.D., Se Hoon M.D., Ph.D., Jaeho M.D., Ph.D., Jun Won M.D., Jong Hee M.D., Ph.D., Dong Suk M.D., Ph.D., Kyu Sung M.D., Ph.D., Chang-Ok M.D., Ph.D.,